JP2016535098A5 - - Google Patents

Download PDF

Info

Publication number
JP2016535098A5
JP2016535098A5 JP2016551069A JP2016551069A JP2016535098A5 JP 2016535098 A5 JP2016535098 A5 JP 2016535098A5 JP 2016551069 A JP2016551069 A JP 2016551069A JP 2016551069 A JP2016551069 A JP 2016551069A JP 2016535098 A5 JP2016535098 A5 JP 2016535098A5
Authority
JP
Japan
Prior art keywords
compound
pharmaceutically acceptable
acceptable salt
formula
carboxamide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2016551069A
Other languages
English (en)
Japanese (ja)
Other versions
JP6479834B2 (ja
JP2016535098A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/GB2014/053236 external-priority patent/WO2015067923A1/en
Publication of JP2016535098A publication Critical patent/JP2016535098A/ja
Publication of JP2016535098A5 publication Critical patent/JP2016535098A5/ja
Application granted granted Critical
Publication of JP6479834B2 publication Critical patent/JP6479834B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2016551069A 2013-11-05 2014-10-30 Nmdaアンタゴニストプロドラッグ Active JP6479834B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361899903P 2013-11-05 2013-11-05
US61/899,903 2013-11-05
PCT/GB2014/053236 WO2015067923A1 (en) 2013-11-05 2014-10-30 Nmda antagonist prodrugs

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2019018440A Division JP6633233B2 (ja) 2013-11-05 2019-02-05 Nmdaアンタゴニストプロドラッグ

Publications (3)

Publication Number Publication Date
JP2016535098A JP2016535098A (ja) 2016-11-10
JP2016535098A5 true JP2016535098A5 (cg-RX-API-DMAC7.html) 2019-01-24
JP6479834B2 JP6479834B2 (ja) 2019-03-06

Family

ID=51947383

Family Applications (4)

Application Number Title Priority Date Filing Date
JP2016551069A Active JP6479834B2 (ja) 2013-11-05 2014-10-30 Nmdaアンタゴニストプロドラッグ
JP2019018440A Active JP6633233B2 (ja) 2013-11-05 2019-02-05 Nmdaアンタゴニストプロドラッグ
JP2019222567A Active JP6856737B2 (ja) 2013-11-05 2019-12-10 Nmdaアンタゴニストプロドラッグ
JP2021044193A Active JP7234278B2 (ja) 2013-11-05 2021-03-18 Nmdaアンタゴニストプロドラッグ

Family Applications After (3)

Application Number Title Priority Date Filing Date
JP2019018440A Active JP6633233B2 (ja) 2013-11-05 2019-02-05 Nmdaアンタゴニストプロドラッグ
JP2019222567A Active JP6856737B2 (ja) 2013-11-05 2019-12-10 Nmdaアンタゴニストプロドラッグ
JP2021044193A Active JP7234278B2 (ja) 2013-11-05 2021-03-18 Nmdaアンタゴニストプロドラッグ

Country Status (25)

Country Link
US (4) US9822075B2 (cg-RX-API-DMAC7.html)
EP (3) EP4001272B1 (cg-RX-API-DMAC7.html)
JP (4) JP6479834B2 (cg-RX-API-DMAC7.html)
KR (2) KR102469167B1 (cg-RX-API-DMAC7.html)
CN (2) CN105683180B (cg-RX-API-DMAC7.html)
AR (1) AR098319A1 (cg-RX-API-DMAC7.html)
AU (1) AU2014345407B2 (cg-RX-API-DMAC7.html)
CA (1) CA2928004C (cg-RX-API-DMAC7.html)
CY (1) CY1121749T1 (cg-RX-API-DMAC7.html)
DK (1) DK3066091T3 (cg-RX-API-DMAC7.html)
ES (3) ES2999064T3 (cg-RX-API-DMAC7.html)
HR (2) HRP20191159T1 (cg-RX-API-DMAC7.html)
HU (2) HUE070532T2 (cg-RX-API-DMAC7.html)
LT (1) LT3066091T (cg-RX-API-DMAC7.html)
MX (2) MX394633B (cg-RX-API-DMAC7.html)
PL (2) PL4001272T3 (cg-RX-API-DMAC7.html)
PT (1) PT3066091T (cg-RX-API-DMAC7.html)
RS (2) RS58991B1 (cg-RX-API-DMAC7.html)
RU (1) RU2695372C2 (cg-RX-API-DMAC7.html)
SI (1) SI3066091T1 (cg-RX-API-DMAC7.html)
SM (1) SMT202500023T1 (cg-RX-API-DMAC7.html)
TR (1) TR201909632T4 (cg-RX-API-DMAC7.html)
TW (1) TW201609653A (cg-RX-API-DMAC7.html)
UY (1) UY35823A (cg-RX-API-DMAC7.html)
WO (1) WO2015067923A1 (cg-RX-API-DMAC7.html)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RS58991B1 (sr) 2013-11-05 2019-08-30 Astrazeneca Ab Prolekovi nmda antagonista
US11358935B2 (en) 2016-11-28 2022-06-14 Biohaven Pharmaceutical Holding Company Ltd. Prodrugs of lanicemine and their method of use
CN107578281B (zh) * 2017-08-31 2021-03-30 湖南大学 电子商务环境下用户优惠券行为预测方法及模型构建方法
BR112022025900A2 (pt) * 2020-06-23 2023-01-10 Biohaven Therapeutics Ltd Formulações tópicas de (1s)-1-fenil-2-piridin-2-iletanamina
WO2025137661A1 (en) * 2023-12-22 2025-06-26 Biohaven Therapeutics Ltd. Combination treatment of neurological disorders

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE7909514L (sv) 1979-11-16 1981-05-17 Astra Laekemedel Ab Nya halofenyl-pyridyl-allylaminderivat
US4769466A (en) * 1987-02-06 1988-09-06 Pennwalt Corporation 2-aminoacetamide pyridinyl derivatives
EP0356035B1 (en) * 1988-08-12 1996-03-13 Astra Aktiebolag Arylkalkyl-amines and -amides having anticonvulsant and neuroprotective properties
RU2128650C1 (ru) 1992-04-03 1999-04-10 Астра АБ (S)-α-ФЕНИЛ-2-ПИРИДИНЭТАНАМИН И ЕГО СОЛЬ С НЕОРГАНИЧЕСКИМИ КИСЛОТАМИ, СПОСОБ ИХ ПОЛУЧЕНИЯ, ЛЕКАРСТВЕННЫЙ ПРЕПАРАТ НА ИХ ОСНОВЕ И СПОСОБ ЛЕЧЕНИЯ СУДОРОГ
SE9901077D0 (sv) 1999-03-23 1999-03-23 Astra Ab Novel use
SE9901340D0 (sv) 1999-04-15 1999-04-15 Astra Pharma Prod Novel process
US6613879B1 (en) * 1999-05-14 2003-09-02 Boehringer Ingelheim Pharma Kg FAP-activated anti-tumour compounds
PE20020291A1 (es) 2000-08-21 2002-04-17 Hoffmann La Roche Profarmacos para ligandos del receptor nmda
ATE380029T1 (de) 2001-06-11 2007-12-15 Xenoport Inc Prodrugs von gaba-analoga, zusammensetzungen und ihre verwendungszwecke
GB0310593D0 (en) * 2003-05-08 2003-06-11 Leuven K U Res & Dev Peptidic prodrugs
EP2371815A1 (en) 2003-12-30 2011-10-05 XenoPort, Inc. Sythesis of acyloxyalkyl carbamate prodrugs and intermediates thereof
EP1929030A2 (en) * 2005-09-08 2008-06-11 Shire LLC Prodrugs of t3 and t4 with enhanced bioavailability
CN101246417B (zh) 2007-02-13 2010-09-29 艾威梯科技(北京)有限公司 音频数据流输入/输出无间断软件切换的方法和系统
ES2601852T3 (es) 2008-01-25 2017-02-16 Xenoport, Inc. Forma cristalina de sales de calcio de ácidos (3S)-aminometil-5-metil-hexanoicos y métodos de uso
WO2010017504A1 (en) * 2008-08-07 2010-02-11 Xenoport, Inc. Methods of synthesizing 1-(acyloxy)-alkyl carbamate prodrugs
US9062094B2 (en) * 2010-01-22 2015-06-23 Ascendis Pharma As Dipeptide-based prodrug linkers for aliphatic amine-containing drugs
WO2013023155A1 (en) * 2011-08-11 2013-02-14 Xenoport, Inc. Anhydrous and hemihydrate crystalline forms of an (r)-baclofen prodrug, methods of synthesis and methods of use
RS58991B1 (sr) 2013-11-05 2019-08-30 Astrazeneca Ab Prolekovi nmda antagonista

Similar Documents

Publication Publication Date Title
JP2016535098A5 (cg-RX-API-DMAC7.html)
JP2013509429A5 (cg-RX-API-DMAC7.html)
NZ603236A (en) Boronate ester compounds and pharmaceutical compositions thereof
SA515360229B1 (ar) مثبطات‎ ‎عامل التمايز والنمو 8‏
UA107112C2 (uk) Активатори розчинної гуанілатциклази
NZ626985A (en) Combination therapy (vemurafenib and a mdm2 inhibitor) for the treatment proliferative disorders
EA201100030A1 (ru) Пиразольные соединения 436
JO2885B1 (en) Protein kinase inhibitors
EA201100928A1 (ru) Новые 4-амино-4-оксобутаноил-пептиды как ингибиторы репликации вирусов
SG10201405826RA (en) Inhibitors of influenza viruses replication
NZ595168A (en) Hepatitis c virus inhibitors
JP2008255122A5 (cg-RX-API-DMAC7.html)
JP2013518107A5 (cg-RX-API-DMAC7.html)
RU2015119517A (ru) Новый способ лечения инфаркта миокарда с применением фрагмента hmgb1
MX360030B (es) Metodos para tratar el trastorno bipolar.
EA201391337A1 (ru) Ингибиторы hsp90
JP2012519182A5 (cg-RX-API-DMAC7.html)
JP2011523952A5 (cg-RX-API-DMAC7.html)
NZ593524A (en) A nonapeptide with anti-tumour activity
CY1120852T1 (el) Φαρμακευτικη συνθεση η οποια περιλαμβανει ιβουπροφαινη, τραμαδολη και ενα βασικο αμινοξυ, μεθοδος παρασκευης αυτης και χρηση της ιδιας
PE20110677A1 (es) Polimorfo b de la n-(2-aminofenil)-4-[n-(piridin-3-il) metoxicarbonilamino-metil]benzamida (ms-275)
RU2016119493A (ru) Пролекарства антагониста NMDA
CY1118036T1 (el) Βελτιστοποιημενη συνθεση καθαρων μη-πολυμορφικων, κρυσταλλικων χολικων οξεων με καθορισμενο μεγεθος σωματιδιων
AR090592A1 (es) Sales de 5-[(1r)-2-({2-[4-(2,2-difluoro-2-feniletoxi)fenil]etil}amino)-1-hidroxietil]-8-hidroxiquinolin-2(1h)-ona
JP2014519507A5 (cg-RX-API-DMAC7.html)